New Import Rules to Boost Pharmaceutical Research in India
In a landmark move to enhance research and innovation while streamlining the business landscape within the pharmaceutical industry, the Union Ministry of Health and Family Welfare has announced proposed amendments to the Drugs Rules, 1945. These adjustments are aimed at simplifying the process for obtaining permission to import drugs for examination, testing, or analysis, a procedure known as Form 11.
The proposed changes introduce an acknowledgment-based system for the importation of small quantities of drugs intended for analytical and non-clinical testing. Under the new guidelines, applicants wishing to import these drugs will only need to submit a prior intimation form. Once this is done, they can proceed with the import based on the acknowledgment generated upon submission.
This streamlined procedure will apply to most drugs imported for analytical and non-clinical testing. However, certain categories, including sex hormones, cytotoxic drugs, beta lactam drugs, biologics containing live microorganisms, and narcotic and psychotropic substances, will still require prior licensing.
Notably, this amendment builds on earlier modifications made to the New Drugs and Clinical Trials Rules in January 2026, which had already introduced a notification system for domestic test licenses. The current proposal extends similar benefits to the import sector.
The expected impact of this amendment is significant, as it will drastically reduce the compliance burden on applicants by doing away with licensing requirements for small-scale importation of drugs for research or development purposes. This change is poised to dramatically deregulate the research and development sector in pharmaceuticals, enabling startups and industries to initiate testing or analysis much more swiftly. Moreover, the online intimation system is set to create a seamless and prompt gateway for stakeholders in the sector.
This initiative is anticipated to deliver substantial support to research and innovation across the country while improving the regulatory process to make it more efficient and straightforward. Furthermore, it aligns with the Government’s ongoing efforts to refine the regulatory framework, enhance ease of doing business, and promote innovation within the pharmaceutical landscape.
The draft notification is now available for public review, allowing stakeholders to provide feedback. Suggestions and objections can be submitted to the Under Secretary (Drugs) at the Ministry of Health and Family Welfare, or via email at [email protected].
The draft Gazette Notification can be accessed at: here.
Observer Voice is the one stop site for National, International news, Sports, Editor’s Choice, Art/culture contents, Quotes and much more. We also cover historical contents. Historical contents includes World History, Indian History, and what happened today. The website also covers Entertainment across the India and World.
